Search
for
Sort by
Research 421–450 of 1000+
- Generation of human-induced pluripotent stem cell-derived adherent 3-dimensional skin hair-follicle organoids
- Comment on “Low dose oral minoxidil for treating alopecia: A 3-year North American retrospective case series”: Adding further evidence about side effects
- Crystal Structure and Synthesis of 17α-Hexanoyloxy-16β-methylpregna-4,6-diene-3,20-dione
- NTP Toxicology and Carcinogenesis Studies of C.I. Acid Orange 3 (CAS No. 6373-74-6) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
- The neurosteroid metabolite of progesterone, 3α‐OH‐dihydroprogesterone (3α‐OH‐DHP), is required for attenuated baroreflex mediated sympathoexcitation in pregnancy
- Impact of Disease History on the Efficacy of Ritlecitinib in Patients With Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- Katsuwonus pelamis heart hydrolysates promote hair growth in 3-dimensional human hair follicle organoids and in mice
- iPrimer-seq: A Streamlined and Cost-Effective Early-Barcoding 3'-End Rna-Seq Method for Transcriptome Profiling from Limiting Cell Inputs
- Tuning Scaffold Properties of New 1,4-Substituted Pyrrolo[3,2-c]quinoline Derivatives Endowed with Anticancer Potential, New Biological and In Silico Insights
- Updated Integrated Efficacy Analysis of Ritlecitinib Up to 3 Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials
- Evaluación pronóstica de la escala delta-sofa a los 3 y 5 días del ingreso en uci asociado al saps 3 y creación de un modelo objetivo para la adecuación ética del esfuerzo terapéutico
- 49690 Long-term efficacy of baricitinib in alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2
- Reviewer #1 (Public Review): CaBP1 and 2 enable sustained CaV1.3 calcium currents and synaptic transmission in inner hair cells
- The study of the range and availability of Vitamin D 3 preparations in the pharmaceutical market of Ukraine
- Discovery of (2<i>S</i>)-<i>N</i>-(6-Cyano-5-(trifluoromethyl)pyridin-3-yl)-3-(6-(4-cyanophenyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)-2-hydroxy-2-methylpropanamide as a Highly Potent and Selective Topical Androgen Receptor Antagonist for Androgenetic Alopecia Treatment
- Sustained Scalp, Eyebrow, and Eyelash Hair Regrowth with Ritlecitinib Through Week 48 in Patients with Alopecia Areata: Post-Hoc Analysis of the ALLEGRO Phase 2b/3 Study
- 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
- 32237 Clinician and patient evaluation of improvement for eyebrow and eyelashes hair loss during baricitinib phase 3 trials BRAVE-AA1 and BRAVE-AA2
- Book Review: “Integrated Procedures in Facial Cosmetic Surgery” ISBN 978-3-030-46992-4 ISBN 978-3-030-46993-1 (eBook) © Springer Nature Switzerland AG 2021
- An Adult With Hair Loss! a Rare Case of Non-Classical 3β Hydroxysteroid Dehydrogenase (3β HSD) Deficiency
- Safety and efficacy of actinic keratoses reduction with a 3 day application of ingenol disoxate field treatment to the face, chest and balding scalp
- Review of the ISHRS Regional Workshop for Assistant Training May 1-3, 2015 • Denver, Colorado
- Electronic Brachytherapy for the Treatment of Nonmelanoma Skin Cancer: Results at 3 Years
- Hair Transplants Results Using FUE – Hair Restoration for Level 3 Hair Loss
- Crystal Structure of 17-.BETA.-Benzoyloxy-16-.BETA.-methylpregna-4,6-diene-3,20-dione.
- 17α-Acetoxy-6-bromo-16β-methylpregna-4,6-diene-3,20-dione
- American Society of Hair Restoration Surgery 1998 Annual Meeting – Feburary 1-3, New Orleans
- American College of Clinical Pharmacology Twenty‐Second Annual Meeting November 1–3, 1993 Boston, Massachusetts